AM630 is primarily used in research settings as a selective antagonist for the cannabinoid receptor CB2. It plays a crucial role in studying the function and signaling pathways of CB2 receptors, which are involved in immune system regulation and inflammatory responses. Researchers utilize AM630 to investigate its potential therapeutic applications in conditions like chronic pain, inflammation, and autoimmune diseases. Additionally, it helps differentiate the effects of CB2 receptors from CB1 receptors, aiding in the development of targeted cannabinoid-based therapies. Its application is limited to experimental and preclinical studies, contributing to a deeper understanding of the endocannabinoid system.